Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did you look up the firm and the guy mentioned in the filing?
Thanks sox,
Less then 1% of the shares short is very small compared to other companies I follow
Are you talking 4B after this phase or phase 3?
Thanks sox, that really helps to understand
Abstract was embargoed until 2 hours ago
Any science people left here? This was just released
AACR Annual Meeting 2017 Online Proceedings and Itinerary Planner Home Print Page
Share Page
Session PO.ET06.10 - Novel Molecular Targets 2
3221 / 22 - Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies
Add To My Itinerary
April 4, 2017, 8:00 - 12:00 PM Section 8
Presenter/Authors
Ashok Kumar1, David P. Brennan1, Karima Chafai-Fadela1, Sylvia A. Holden1, Siya Ram1, Geoffrey I. Shapiro2, Krishna Menon1. 1Cellceutix Corporation, Beverly, MA; 2Dana-Farber Cancer Institute, Boston, MA
Disclosures
A. Kumar: ; Cellceutix Corporation. D.P. Brennan: ; Cellceutix Corporation. K. Chafai-Fadela: ; Cellceutix Corporation. S.A. Holden: ; Cellceutix Corporation. S. Ram: ; Cellceutix Corporation. G.I. Shapiro: ; Cellceutix Corporation. K. Menon: ; Cellceutix Corporation.
Abstract
Ovarian cancer (OC) is a molecularly and histologically heterogeneous disease; however, standard treatment is the same for all subtypes. High-grade serous OC initially responds to chemotherapy; however, low-grade serous and clear cell OC are relatively chemoresistant. Limited treatment options are available upon recurrence. p53 mutations are found in over 90% of high-grade serous OC. Low-grade serous OC harbor wild type p53, but contain other mutations. During later stages of OC, tumors are a heterogeneous population of mutant cells; thus, development of a novel drug that addresses these molecular differences is highly desirable. Previously, we showed that Kevetrin stabilized wild type p53 and induced transcriptional targets in human lung carcinoma. We sought to validate Kevetrin as a potential treatment for OC with varied p53 status. Endometrioid carcinoma (A2780, wt p53), atypical non-serous clear cell (SKOV-3, deleted p53), and high-grade serous (OVCAR-3, mutant p53) OC cell lines were treated with Kevetrin. Kevetrin induced apoptosis in all three OC cell lines, as assayed by cleavage of PARP and caspase-3. Studies showed significant increases in p53 and p21 protein levels in A2780 cells in 24 to 48 hours; however, in OVCAR-3, Kevetrin downregulated oncogenic mutant p53. RNA levels of p53 and p21 were quantified by qRT-PCR 8 to 72 hours after treatment. No significant changes were observed in p53 mRNA, whereas an increase in p21 mRNA was observed in all three cell lines. In A2780, Kevetrin also induced levels of PUMA in a dose-dependent manner. To establish that Kevetrin mediates increased p21 expression requiring p53 in A2780 cells, p53 was depleted by siRNA. p53 depletion reduced p21 expression, as assayed by FACS, indicating p53 directs p21 expression in a dose-dependent manner after Kevetrin treatment. In an in vivo xenograft study in immunocompromised nude mice bearing established A2780 tumors, Kevetrin treatment inhibited tumor growth at well-tolerated doses. The mode of action in vivo also showed enhanced expression of p21 in tumor tissue, indicating p53 pathway activation in A2780 tumors. In contrast, in SKOV-3 cells and xenografts, a p53 independent increase in p21 expression was observed. In OVCAR-3 cells,Kevetrin altered the expression of three microRNAs (miRNA-27a, miRNA-1274b, miRNA-25), that are known to be dysregulated in OC, in a time-dependent manner. To gain further insight into the mechanism of action in cells with diverse p53 status, RNA-Seq is being performed in the three cell lines and tumor tissue from mice before and after Kevetrin exposure. In summary, Kevetrin has promise as an effective therapeutic agent for endometrioid, non-serous clear cell, and high-grade serous OC, with molecularly diverse p53 status. A Phase 1 clinical study was completed and a Phase 2 clinical study in ovarian cancer is scheduled to begin January 2017.
AACR Annual Meeting
Yeah, that wasn't too hard to figure out
Ty loanranger,
I went back and looked and now also noticed the number of institutions is 2. I also used to look at MSN but haven't been paying attention closely
Thank you LR,
When looking for that I noticed bahoo had 1.70% institutional ownership of CTIX. Does that include aspire and would you have any idea of when that updates and if this is a change?
Tyia
Quarterly report was released feb. 8 last year
Wow, unreal, way to stick it to him sox
After the first article I doubt many even read this article. It looks really desperate at this point.
It will be a fun ride
The monolith posted this earlier
"Going to a few pennies eventually. Probably test 60 cents end of the year. Maybe 80 soon before bouncing back to 1.20?"
Sure seems familiar doesn't it?
You put that very nicely!
Thank you!
Your still pouting because Leo ignored you at the showcase?
Great point!!!
Just read apple hit .91 cents in 2003.
Looks like Ctix following a similar pattern.
http://www.investopedia.com/stock-analysis/cotd/012517/apple-price-levels-watch-after-earnings-aapl-aapl.aspx?partner=YahooSA&yptr=yahoo
Wow, great article. Had no idea who this guy was.
Don't forget to hit the link of Adam who?
Ty Jt
The whole point of the post was they used "potent" anti-tumor activity on slide 15.
I then went to the Ctix website and under the Kevetrin tab they used the word " potential"
So is this a big change in evidence?
I hope you are right. Would be nice to get more results. Hopefully soon!!
I noticed on the Ctix website under Kevetrin they use the word potential.
So is this a spelling error in slide 15, or a big change in the claim from potential to potent?
Slide 15 Kevetrin for Ovarian Cancer
"Induces apoptosis and shows potent anti-tumor activity"
Hmm.. interesting
Says NDa approval 4th quarter 2020
Slide 13
4 years away for prurisol to market?
Don't forget to e-mail your friends and family the finra daily short stats also. I'm sure they will be real excited after getting that e-mail every single day
Go Ctix
Took the words right out of my mouth
Hopefully there is alot thinking like you. Should result in bigger upside if results are good and limited downside if bad.
http://finance.yahoo.com/news/cellceutix-receives-preliminary-approval-clinical-140000935.html
He has worked diligently with our CRO (for the planned Phase 3 ABSSSI study). They already have selected the first sites for the study that can start once we get the final protocol approval from the FDA. I wish him and his family well in his new endeavor," said Mr. Ehrlich
Since I only give P a 50/50 chance of success(my own gut feeling), I hope that if the results are bad they release those before the start of the phase III trial of B. I just hope Leo is smart enough to release any bad news first, whether its P or B-om before the great news.
I am leaning towards that being the announcement since they already said they have a couple sites chosen as of a few weeks ago
It says they have a performance goal of 90% to respond in 45 days, that means its a goal, how do we know if they only meeting 50% of that goal? It doesn't surprise me that they a couple days overdue, I suppose it depends on workload and complexity of a new class of antiobotics.
I'm in year 4 of a planned 10 year investment so it doesnt matter to me but I can see how traders are watching for the news.
Have a good day
A frequent speaker and invited lecturer on topics on the diagnosis and management of inflammatory bowel disease, Dr. Farraye has authored or co-authored over 250 original scientific manuscripts, chapters, reviews and abstracts. He is coeditor for the text Bariatric Surgery: A Primer for your Medical Practice and an associate editor for Therapy for Digestive Disorders. He is the series editor for Curbside Consultation in Gastroenterology and co-editor of the text Curbside Consultation in IBD. His most recent book for patients is Questions and Answers about Ulcerative Colitis.
New article on Facebook.
Maybe no partner needed after all? Thoughts?
I didn't need the article but the hundred people not invested that I sent it too might.
Please plan the party during a solar eclipse
The email I got from seeking alpha for the new article came with the link to the mako article. weird
They were trying to promote their pro subscription with a link to the mako article, Im sure it confuses many